The patient has iMCD, which has a poor survival rate and few treatment options but an AI tool searched through 4,000 ...
The PATHWAY HER2 (4B5) test is now FDA-approved to assess HER2-ultralow status in metastatic breast cancer, expanding its ...
13h
Scientists of the University Medical Center Göttingen (UMG) have identified new interactions between pancreatic cancer cells ...
The FDA has approved a companion diagnostic to determine if patients with HR-positive, HER2-ultralow metastatic breast cancer are eligible for T-DXd treatment.
Shanghai Henlius Biotech, Inc. (2696.HK) announced that its anti-PD-1 mAb, HANSIZHUANG (serplulimab, marketed as Hetronifly® in Europe), has been officially approved by the European Commission (EC) ...
A new study shows how an anticancer drug triggers an "outside in" signal that gets it sucked into a cancer cell.
Harbour BioMed (HKEX: 02142, the "Company"), a global biopharmaceutical company committed to the discovery, development and commercialization of novel antibody therapeutics focusing on immune-oncology ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback